A Novel Dual-Targeting Molecular Probe TATE-RGD for Diagnosing Tumors Positive for SSTR2 and Integrin 23

What this Trial Is About

Researchers are evaluating a new dual-targeting molecular probe called 68Ga-TATE-RGD for imaging tumors that express somatostatin receptor 2 (SSTR2) and integrin 23. This study focuses on patients with tumors such as small cell lung cancer, pulmonary carcinoid, medullary thyroid cancer, and neuroendocrine tumors (NETs) that show positive expression of these receptors. The goal is to improve tumor detection and explore potential therapeutic uses of this dual-target tracer compared to existing single-target tracers. Participants will receive intravenous injections of the imaging agents 68Ga-TATE-RGD and 18F-FDG at specified doses for PET/CT and SPECT/CT scans. About 30 patients with confirmed positive expression of SSTR2 and integrin 23 will undergo imaging to assess the tracer's ability to detect tumors. The study is conducted under an early phase 1 protocol with no masking or blinding. During the study, patients will undergo PET/CT and SPECT/CT imaging within a week using the tracers. Researchers will measure tumor detection rates and standardized uptake values (SUV) over an average follow-up of half a year. Assessments include imaging evaluations and monitoring for any medical conditions affecting compliance. The total duration of participation varies but includes imaging and follow-up to evaluate diagnostic performance and tracer kinetics.

A Dual-targeting Tracer TATE-RGD for the Diagnosis of SSTR- and RGD- Positive Tumors